<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0001297'>Stroke</z:hpo> triggers an inflammatory cascade which contributes to a delayed cerebral damage, thus implying that antiinflammatory strategies might be useful in the treatment of <z:hpo ids='HP_0011009'>acute</z:hpo> ischaemic <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Since two unrelated peroxisome proliferator-activated receptor-gamma (PPARgamma) <z:chebi fb="4" ids="48705">agonists</z:chebi>, the thiazolidinedione <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> (RSG) and the cyclopentenone <z:chebi fb="11" ids="26333">prostaglandin</z:chebi> <z:chebi fb="0" ids="34159">15-deoxy-Delta(12,14)-prostaglandin J2</z:chebi> (15d-PGJ2), have been shown to possess antiinflammatory properties, we have tested their neuroprotective effects in experimental <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="50122">Rosiglitazone</z:chebi> or 15d-PGJ2 were administered to rats 10 mins or 2 h after permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0001297'>Stroke</z:hpo> outcome was evaluated by determination of <z:mpath ids='MPATH_124'>infarct</z:mpath> volume and assessment of neurological scores </plain></SENT>
<SENT sid="4" pm="."><plain>Brains were collected for protein expression, gene array analyses and gene shift assays </plain></SENT>
<SENT sid="5" pm="."><plain>Our results show that both compounds decrease MCAO-induced <z:mpath ids='MPATH_124'>infarct</z:mpath> size and improve neurological scores </plain></SENT>
<SENT sid="6" pm="."><plain>At late times, the two compounds converge in the inhibition of MCAO-induced brain expression of inducible NO synthase and the matrix metalloproteinase 9 </plain></SENT>
<SENT sid="7" pm="."><plain>Interestingly, at early times, complementary DNA microarrays and gene shift assays show that different mechanisms are recruited </plain></SENT>
<SENT sid="8" pm="."><plain>Analysis of early nuclear p65 and late cytosolic IkappaBalpha protein levels shows that both compounds inhibit nuclear factor-kappaB signalling, although at different levels </plain></SENT>
<SENT sid="9" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> these results suggest both PPARgamma-dependent and independent pathways, and might be useful to design both therapeutic strategies and prognostic markers for <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
</text></document>